Description
Composition
Each tablet contains:
- Cabergoline – 0.5 mg
- Excipients – q.s.
Pharmacological Effects
- Dopaminergic Action: Selectively activates dopamine D₂ receptors in the pituitary gland, inhibiting prolactin secretion.
- Endocrine Modulation: Suppresses prolactin production and release from lactotroph cells.
- CNS Effects: Crosses the blood-brain barrier to exert central dopaminergic effects.
- Long Duration: Extended half-life (63–69 hours) allows for twice-weekly dosing.
- Ergot-Related Effects: Mild serotonin and α-adrenergic receptor activity at higher doses.
Indications
- Hyperprolactinemia (primary treatment)
- Parkinson’s Disease (adjunct therapy)
- Pituitary Adenomas (prolactin-secreting)
Recommended Dose
For Hyperprolactinemia:
- Initial Dose: 0.25 mg twice weekly
- Titration: Increase by 0.25 mg weekly (max 1 mg twice weekly)
- Maintenance: Lowest effective dose (typically 0.25–0.5 mg twice weekly)
For Parkinson’s Disease:
- Initial: 0.5 mg once daily
- Max Dose: 4 mg/day (in divided doses)
Side Effects
Common: Nausea, headache, dizziness, fatigue
Serious: Cardiac valvopathy (with long-term/high-dose use), psychiatric effects (impulse control disorders)
Contraindication
- History of cardiac valvular disorders
- Uncontrolled hypertension
- Pregnancy (except for macroprolactinoma treatment)
- Hypersensitivity to ergot derivatives
Storage Conditions
- Store below 30°C
- Protect from light and moisture
Disclaimer: Always follow your healthcare provider’s advice regarding storage and use.
Reviews
There are no reviews yet.